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INTRODUCTION:  Letrozole,  an  aromatase  inhibitor,  is a commonly  used  neo-adjuvant  drug  to treat
hormone-sensitive  breast  cancer.  There  have  been  a  few  cases  of  aromatase  inhibitor  induced  vasculitis
but  the ﬁrst  case  of letrozole-induced  vasculitis  was  reported  from  Switzerland  in 2014  (Digklia  et  al.)
[1].
PRESENTATION  OF  CASE:  We report  the  case  of  a 72-year-old  woman  with  a small  breast  cancer.  She  was
started  on pre-operative  letrozole  (2.5 mg/d)  whilst  awaiting  surgery.  Ten  days  later  she  presented  with
burning  pain  and  purpuric  skin  lesions  which  progressed  to extensive  ischaemic  superﬁcial  necrosis  of
the lower  limb  skin,  resolving  over  3–4 months  after  local and  systemic  steroids.  Histologically,  it showed
leucocytoclasis  with  evidence  of  eosinophilia  consistent  with  a  diagnosis  of cutaneous  leukocytoclastic
small  vessel  vasculitis.
DISCUSSION:  The  initial  clinical  presentation  was  severe  burning  pain  around  the  ankles  and  a  spreading
violaceous  rash.  Letrozole  was stopped.  Wide  local  excision  (lumpectomy)  and sentinel  node  biopsy  were
postponed  because  of  the accompanying  pneumonitis  and  gastrointestinal  upset,  and  were  carried  out 3.5
months  later.  Fortunately,  the  tumour  size  did not  increase,  but appeared  to  reduce,  and axillary  lymph
nodes  remained  negative,  i.e.,  this  patient’s  cancer  outcome  does  not  seem  to  have  been  jeopardized.
CONCLUSION:  Leukocytoclastic  vasculitis  is  a hypersensitivity  reaction  that  is  usually  self-resolving,
though  our  case  needed  systemic  steroid  treatment.  Letrozole  is  a commonly  used drug  in  clinical  prac-
tice  and  prescribers  should  be aware  of  this  rare side  effect,  which  in  our  case  delayed  treatment  without
any  apparent  harm  and  possibly  reduced  tumour  size.
.  Pub
he  CC©  2015  The  Authors
access  article  under  t
. Introduction
Aromatase inhibitors have replaced tamoxifen as the preferred
djuvant endocrine treatment in the majority of postmenopausal
reast cancer patients. They inhibit or inactivate the aromatase
nzyme and therefore inhibit oestrogen synthesis in peripheral fat,
he main source of oestrogen after menopause. Generally, they are
ell-tolerated and common side effects include nausea, vomiting,
Abbreviations: PCR, protein creatinine ratio; ANCA, anti-neutrophil cytoplasmic
ntibody; CLSVV, cutaneous leukocytoclastic small vessel vasculitis; HE, hema-
oxylin and eosin stain.
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alopecia, dry skin and osteoporosis. Cutaneous manifestations are
rare, with few documented cases of erythema nodosum, cutaneous
vasculitis, toxic epidermal necrolysis, Henoch-Schönlein purpura,
and cutaneous lupus erythematosus [2–8].
A vasculitis secondary to letrozole has been reported in
Switzerland [1] but to the best of our knowledge, this is the only
other case reported in the world.
2. Presentation of case
A 72 year old woman with left-sided invasive lobular carcinoma
of the breast (18 × 8 × 7 mm on ultrasound, Grade 2, ER positive,
PR positive, HER2 negative, Mib-1/Ki67 proliferation index 15%)
was scheduled to have a wide local excision of the cancer (lumpec-
tomy) and sentinel node biopsy. However, due to her wish to visit
iates Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Dig. 1. Images taken on the ﬁrst day and a week later showing palpable purpura a
015,  Right 24th Feb 2015.
er elderly husband in Ireland, the surgery was  postponed and
etrozole was started in the meantime. She was taking amlodip-
ne and bendroﬂumethiazide for hypertension, digoxin and aspirin
or atrial ﬁbrillation, simvastatin, occasionally a salbutamol inhaler
or asthma, and co-codamol for knee pain. She has no known drug
llergies.
A day before the surgery (i.e 14 days after starting letrozole)
he patient gave a four-day history of a severe burning sensation
round both ankles. The overlying skin had an erythematous and
iolaceous rash with blisters and was tender on palpation (Fig. 1).
he gave a two-day history of vomiting and diarrhoea as well
s a productive cough and wheeze, but no haematemesis and no
aemoptysis.
Urine dipstick showed mild proteinuria and Protein Creatinine
atio (PCR) of 48 (normal range: <45 mg/mmol), but no haema-
uria. Her observations including blood pressure (131/81 mmHg)
ere all normal and blood cultures did not show any growth.
nti-Nuclear Antibody was  negative, Anti-Neutrophil Cytoplasmic
ntibody (ANCA) was negative but complement C4 was raised to
1 mg/dL (normal range: 20–40 mg/dL). A diagnosis of vasculitis,
ossibly related to letrozole use, was considered and a skin punch
iopsy of the rash on the right leg was taken (Fig. 1).
Letrozole was stopped and the patient was started on topical
teroid, clobetasol propionate 0.05% (Dermovate). The pneumonitis
nd gastrointestinal upset meant that the scheduled lumpectomy
ad to be cancelled. Amoxicillin was started.
Five days later there was increased burning sensation around
oth ankles and lower legs (Fig 1, right). There was circumferential
ecrosis on the right leg and multiple non-exudative violaceous
mall lesions extending to both upper thighs and lower back. There
as breakdown of the skin with crusting of coalescent areas. Theight leg was warm to touch and pedal oedema extended to the
id-shin. She was unable to tolerate clobetasol propionate due to
ntense pain when applying it and instead was started on analgesia
ig. 2. Left HE; ×100 magniﬁcation: Necrotic epidermis lies partly detached from the u
ermal changes of ﬁbrinoid necrosis involving small vessels, karyorrhectic debris (leucoclaceous macules becoming conﬂuent with superﬁcial skin necrosis: Left 17th Feb
and 40 mg  of oral Prednisolone. She was admitted for observation
and pain relief.
By this time, the histopathology of the punch biopsy was avail-
able and showed extensive ischaemic necrosis of the epidermis
and the papillary dermis, with the formation of a sub-epidermal
blister. There was  interstitial haemorrhage with scattered nuclear
dust and karyorrhectic debris (leucocytoclasis). Neutrophils and
eosinophils surrounded the blood vessels and there was inﬁltration
of vessel walls with ﬁbrinoid necrosis, consistent with a diagnosis
of cutaneous leukocytoclastic small vessel vasculitis (Fig. 2).
Renal function improved quickly, ruling out signiﬁcant renal
involvement. Three days later the legs were still painful but the
erythematous area had decreased in size. The following week
there were no new lesions but there was  extensive superﬁcial skin
necrosis. The prednisolone dose was  tapered off. Letrozole was
not re-introduced. The lesions healed over the next 10–12 weeks
(Fig. 3).
Three and a half months after the initial scheduled surgery (17th
February 2015), the patient underwent wire guided wide local exci-
sion of the tumour and sentinel node biopsy on 2nd June 2015.
The ﬁnal pathology report conﬁrmed a 12 mm invasive lobular
carcinoma excised with clear margins. Lymphovascular invasion
was absent and the sentinel lymph node was  free of metastasis.
She received postoperative breast radiotherapy with tumour bed
boost and is currently on tamoxifen (20 mg/d), a selective oestro-
gen receptor modulator (SERM), rather than an aromatase inhibitor
for adjuvant systemic therapy.
3. DiscussionLeukocytoclastic vasculitis is an immune complex-mediated
reactive transient small-vessel vasculitis. It causes 10–20% of all
small-vessel vasculitides [9]. Cutaneous leukocytoclastic small ves-
sel vasculitis (CLSVV) is a diagnosis of exclusion, and infection and
nderlying dermis to form a subepidermal blister. Right HE; ×200 magniﬁcation:
ytoclasis) and red blood cell extravasation.
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tig. 3. The lesions at 1 month top left (18th March 2015), 6 weeks top right (30th
015),  and 18 weeks bottom left and bottom right (both 15th June 2015).
onnective tissue disease need to be ruled out by negative ANCA
evels and through biopsy. Over 100 drugs have been known to
ause either CLSVV or drug-induced lupus, though the absolute
requency of drug-induced vasculitis is approximately 1/100,000
eople [10,11].
The pathogenesis of aromatase inhibitor induced vasculitis is
ot fully understood. It is thought that higher circulating oestro-
en levels inhibit neutrophil function. Therefore, the reduction of
estrogen due to aromatase inhibition could increase neutrophil
ctivity. This would account for the high levels of neutrophils seen
n the biopsy. Neutrophils adhere to the blood vessel endothe-
ium, resulting in autoimmunity [12]. Similar case reports have
lso postulated that the down-regulation of oestrogen could in fact
irectly induce vasculitis [4,6]. A similar vasculitic reaction around
he ankles occurred in a patient after commencing letrozole inh 2015), 12 weeks middle left (11th May  2015), 14 weeks middle right (20th May
Switzerland in 2014 [1]. As this is a hypersensitivity reaction, not
an allergy, we do not believe that the preservatives or excipients
could be implicated.
It is important to think about vasculitis as a spectrum. Although
often asymptomatic, patients can present with non-speciﬁc symp-
toms such as fever and malaise, cutaneous symptoms such as
localised pain, pruritus and palpable purpura, or multi-organ failure
affecting the kidney and the lung [13]. Skin lesions arise in clusters
and commonly affect the lower legs and ankles [14].
The CLSVV in this patient was  histologically characterised by
three main features. Firstly, karyorrhexis of neutrophil nuclei,
also known as leucocytoclasis. Secondly, vascular damage from
the leukocytoclastic granules and ﬁbrinoid necrosis. Thirdly, the
presence of tissue eosinophilia. Though tissue eosinophilia is not
speciﬁc for CLSVV, Bahrami et al. found that it was signiﬁcantly
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ore common in drug-induced CLSVV compared to small-vessel
asculitides not caused by drugs [15].
CLSVV is a transient vasculitis and usually self-limiting. As such,
reatment is often unnecessary. The drug causing the reaction needs
o be removed; and stasis needs to be minimised by compression,
levation and the use of non-steroidal anti-inﬂammatory drugs.
nti-histamines and systemic corticosteroids may  need to be pre-
cribed, particularly when the cutaneous lesions are progressive,
s in our case. Up to 10% of patients could suffer from recurrent
isease.
It is possible that the CLSVV was unrelated to letrozole. It
ight have been related to the pneumonitis, rather than the
ther way round. It is unlikely to have been a paraneoplastic
henomenon [14,16] because the vasculitis improved while the
umour remained in situ and the tumour may  have reduced in size
as discussed below).
It is interesting that the ﬁnal histological tumour size was
maller (12 mm)  than the initial tumour size seen on imaging
15 mm on mammography, 18 mm on ultrasound and 21 mm on
RI); the patient had taken letrozole for less than 2 weeks fol-
owed by nearly 4 months of no speciﬁc treatment for the cancer.
lthough we do not have tumour size measurement when the drug
as stopped, it is unlikely to have reduced so dramatically, so one
ould speculate that the immune reaction leading to the vasculitis
ight have had a tumour suppressive effect.
. Conclusion
In conclusion, we report the second case worldwide of CLSVV
ery likely to be secondary to letrozole treatment. In all patients
ith this presentation, it is important to exclude systemic primary
asculitides, which would require treatment with immunosup-
ressant therapy. CLSVV is a transient hypersensitivity reaction
ith good prognosis. The suspected offending drug needs to be
iscontinued and symptomatic treatment should be given and
ay  need to be supplemented with local and systemic steroids.
lthough exceptionally rare and not life threatening, it is important
o keep in mind this alarming side effect of letrozole, particularly
ecause it is a commonly used drug in breast cancer treatment. It
s interesting that the cancer did not appear to grow during the 4
onths of ‘no-treatment’ after the initial 10–12 days of letrozole
reatment and may  have even shrunk.
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